European Archives - Page 3 of 1531 - European Medical Journal

Merck wins FDA nod for enlicitide oral cholesterol pill

Merck’s enlicitide has received FDA approval as the first oral PCSK9 inhibitor for lowering LDL-C in adults with hypercholesterolemia.

PROTECT-Cog Trial to Test GLP-1 and Cognitive Decline Risk: AAIC 2026

PROTECT-Cog Trial to Test GLP-1 and Cognitive Decline Risk: AAIC 2026

Alzheimer’s Association launches PROTECT-Cog, a global trial testing lifestyle changes plus GLP-1 drugs to reduce cognitive decline risk.

Sertaconazole Nanoemulsion Gel for Fungal Infections - EMJ

Novel Formulation Targets Deep Fungal Skin Infections

A novel sertaconazole nanoemulsion gel improved skin penetration and antifungal efficacy compared with a commercial cream in preclinical testing.

New Sensor Tracks Skin Hydration Atopic Dermatitis - EMJ

Skin Hydration Sensor for Monitoring Atopic Dermatitis at Home

A compact infrared device measures skin hydration in atopic dermatitis, opening the door to objective, home-based eczema monitoring.

Bile Duct Cancer: PNI Linked to Survival Outcomes - EMJ

Perineural Invasion Linked to Poorer ICC Survival Outcomes

Perineural invasion was found in around one third of patients with intrahepatic bile duct cancer and was linked to poorer overall survival in a meta-analysis.

Ferumoxytol Effective Contrast Agent at Low Doses – EMJ

Ferumoxytol Effective Contrast Agent in CMR Even at Low Doses

Ferumoxytol is an effective contrast agent in 3D whole-heart CMR even at low doses, new research has found.

17 Jul 2026

Extracorporeal CO₂ Removal in Clinical Practice

This interactive case study allows clinicians to examine a patient with COPD presenting with an acute exacerbation…

Our latest Nephrology Journal

The latest edition of EMJ Nephrology is now live, distilling high-impact insights and exclusive coverage from ERA 2026 into a concise…

Prof Khaled Musallam

Group Chief Research Officer, Burjeel Holdings; Deputy CEO and Chief of Cell & Gene Therapy and Hematology; Founding Director, Center for…

Discontinuation of GLP-1s Tied to Heightened Psychiatric Risk

Discontinuation of treatment with GLP-1 receptor agonists has been tied to an increased risk of psychiatric events in people with Type 2 diabetes.